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Abstract
Background: The major established etiologic risk factor for bladder cancer is cigarette smoking and one of the major
antineoplastic agents used for the treatment of advanced bladder cancer is cisplatin. A number of reports have suggested
that cancer patients who smoke while receiving treatment have lower rates of response and decreased efficacy of cancer
therapies.
Methodology/Principal Findings: In this study, we investigated the effect of cigarette smoke condensate (CSC) vapor on
cisplatin toxicity in urothelial cell lines SV-HUC-1 and SCaBER cells. We showed that chronic exposure to CSC vapor induced
cisplatin resistance in both cell lines. In addition, we found that the expression of mitochondrial-resident protein adenylate
kinase-3 (AK3) is decreased by CSC vapor. We further observed that chronic CSC vapor-exposed cells displayed decreased
cellular sensitivity to cisplatin, decreased mitochondrial membrane potential (DYm) and increased basal cellular ROS levels
compared to unexposed cells. Re-expression of AK3 in CSC vapor-exposed cells restored cellular sensitivity to cisplatin.
Finally, CSC vapor increased the growth of the tumors and also curtail the response of tumor cells to cisplatin chemotherapy
in vivo.
Conclusions/Significance: The current study provides evidence that chronic CSC vapor exposure affects AK3 expression and
renders the cells resistant to cisplatin.
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Introduction
As per NCI records in United States alone, there are an
estimated 70,980 new cases and 14,330 bladder cancer related
deaths each year, making it the fourth most common cancer in
men and eighth most common cancer in women. Cigarette
smoking has been recognized as the main cause of bladder cancer
and accounts for almost 50% of the cases in developed countries
[1]. Over 4000 compounds have been identified in cigarette
smoke, 60 of which have been found to be complete carcinogens,
tumor initiators, promoters and/or co-carcinogens in various in
vitro and animal bioassays [2]. Secondhand smoke, also known as
passive smoke or environmental tobacco smoke, has been also
associated with bladder cancer, and is the cause of about 38,000
deaths annually in America alone [3]. Reports by the International
Agency for Research on Cancer (IACR) have classified second-
hand tobacco smoke (passive smoking) as an established human
carcinogen [4]. There are over 4000 chemical compounds in
secondhand smoke; 200 of which are known to be poisonous, and
upwards of 60 have been identified as carcinogens [5,6]. Exposure
to secondhand smoke or even just a past smoking history can also
increase the likelihood of bladder cancer in offspring [7].
One of the most commonly used antineoplastic agents for the
treatment of advanced bladder cancer is cisplatin, but the
development of resistance to cisplatin during treatment is common
and constitutes a major obstacle to the cure of sensitive tumors [8].
Although many studies have been conducted on the molecular
mechanism of drug resistance, little is known about the treatment
of these drug-resistant tumors, which still remains a significant
problem. A number of reports have suggested that cancer patients
who smoke while receiving treatment have poorer outcomes
compared with their nonsmoking counterparts, possibly because of
lower rates of response [9]. Retrospective series of patients with
renal[10], bladder[11], and especially glottic cancers[12,13] also
indicate a link between smoking during treatment and decreased
efficacy of cancer therapies. However, there are no direct data
showing that cigarette smoke could actually induce resistance to
chemotherapeutic agents, such as cisplatin.
Deletion of chromosome 9p frequently occurs in bladder
tumors. Depending on the respective investigation, frequencies
between 30 and 70% have been published [14,15]. Studies by
Blaveri et al., [16] indicate that in primary bladder cancer, loss of
clones across the entire chromosome 9 occurs with an average
frequency of 47% for 9p and 46% for 9q. Chromosome 9 carries
important genes involved in adenine metabolism, namely AK1,
AK2 and AK3 (adenylate kinase 1,2 and 3). All three AKs are
nuclear-encoded proteins and synthesized in the cytoplasm. AK1
remains located mainly in the cytosol of different tissues. Mature
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resides in the intermembrane space whereas AK3 is located
exclusively in the mitochondrial matrix [17]. Cigarette smoke is
also known to induce mitochondrial damage as well as dysfunction
[18,19] which may in turn increase cisplatin resistance in bladder
cancer cells [20]. In this study we examined the relationship
between tobacco exposure and cisplatin resistance in relation to
mitochondria function and specifically to a mitochondria-resident
protein AK3. We showed here that cigarette smoke condensate
(CSC) vapor can induce cisplatin resistance. We also found that
the expression of AK3 is affected by CSC vapor and that
restoration of this gene sensitizes the cells to cisplatin.
Results
CSC vapor decreased the expression of AK3 and
increased cisplatin resistance
Human urothelial immortal cell line SV-HUC-1 and bladder
cancer cell line SCaBER was exposed to CSC vapor (passive
smoke) for 6 months and were then designated as HUC1-6M and
SCaBER-6M. We investigated cisplatin sensitivity and mitochon-
drial-residing genes AK2 and AK3 in response to CSC vapor
exposure. In both cell lines, we found that CSC vapor decreased
AK3 expression, whereas AK2 was not affected (Figure 1a). We
also noted that treatment of SV-HUC-1 cells with 0.1% of CSC
for 6 months (HUC1-0.1%6M) also led to a decrease in
expression of AK3 but not AK2. We examined the effect of
cisplatin on SCaBER and SV-HUC-1 cells. Chronic exposure of
the cells to CSC vapor had made the SV-HUC-1 and SCaBER
cells resistance to cisplatin (Figure 1b and 1c). To study the effect
of AK3 expression on the cellular survival of bladder cells in
response to cisplatin, we cloned the full length of AK3 and
transfected the construct into SV-HUC-1, HUC1-6M, SCaBER,
and SCaBER-6M cells. 24 h after transfection with AK3
expression vector or the empty control vector, cells were treated
with or without cisplatin and survival was assessed by the MTT
assay. Treatment of SV-HUC-1 cells with cisplatin revealed that
the cells had acquired resistance to cisplatin upon exposure to
CSC vapor (Figure 1b, compare the solid square to solid triangle).
Over-expression of AK3 in the HUC1-6M resulted in a
significant increase in the sensitivity of the cells to cisplatin
(Figure 1b, compare solid square to open square). Akin to the
results of SV-HUC-1, the SCaBER-6M cells too had acquired
resistance to cisplatin compared to SCaBER parental cells
(Figure 1c, compare solid square to solid triangle). Over-
expression of AK3 in the SCaBER-6M cells resulted in a
significant amount of cell death in response to cisplatin, rendering
the cells more sensitive to cisplatin (Figure 1c, compare closed
square to open square). We also confirmed the survival data with
Calcein AM assay due to the fact that MTT results might be
subjected to altered mitochondrial function (data not shown). In
addition, colony formation assay was performed on SCaBER and
SCaBER-6M which showed that SCaBER-6M was more
resistant to cisplatin which could be reversed by AK3
(Figure 1d). We next attempted to knock down AK3 in SV-
HUC-1 and SCaBER cell lines using AK3 specific RNAi.
Western Blot analysis of the cells 48 h after transfection with AK3
RNAi revealed a successful knockdown of AK3 in the SCaBER
cells but not in the SV-HUC-1 cells (Figure 1e). Treatment of the
cisplatin to these cells revealed that SCaBER cells, but not SV-
HUC-1, became resistant to cisplatin in the presence of AK3
RNAi (Figure 1f and data not shown). This is possibly due to the
fact that AK3 RNAi transfection failed to produce significant
knockdown of the protein in SV-HUC-1 cells. Take together,
these data suggest that CSC vapor renders bladder cells resistant
to cisplatin and that AK3 expression re-sensitizes these cells to the
drug.
To investigate whether the cisplatin sensitivity in these cells
further affected after prolonged CSC treatment, we chronically
exposed the cells to CSC vapor for 11 months. We observed no
significant difference between the cells exposed to CSC vapor for
either 6 and/or 11 months (data not shown), and we thus confined
the remaining experiments to 6 months treatment only, unless
otherwise mentioned.
DYm Alteration by AK3 in the Presence of Cisplatin
Since AK3 is a mitochondrial-resident protein and also affected
cisplatin sensitivity, we next examined how expression of AK3 in
combination with cisplatin affects the mitochondrial membrane
potential of the bladder cells before or after exposure to CSC
vapor. The change in mitochondrial membrane potential (DYm)
was monitored by measuring the shift in the fluorescence of the
emitted light of JC-1. SV-HUC-1 and HUC1-6M cells were
transfected with control vector or AK3 expression plasmid and
then treated with vehicle or cisplatin, before JC-1 staining. We
found that exposure of SV-HUC-1 cells to CSC vapor for 6
months led to a significant decrease in membrane potential of the
cells, consistent with previously reported data [21]. Treatment
with cisplatin for 48 hrs resulted in an increase in number of
depolarized cells in SV-HUC-1 cells from 25.9% to 58.96%, but
to a much lesser extent in HUC1-6M cells. However, when
HUC1-6M cells were treated with cisplatin in presence of forced
expression of AK3, the number of depolarized cells increased from
51.50% to 68.09% (Figure 2a). Similarly, SCaBER-6M cells were
depolarized compared to unexposed parental SCaBER. The
SCaBER-6M showed increased depolarization when treated with
cisplatin in the presence of AK3 overexpression, but to a much
lesser degree with cisplatin alone (Figure 2b).
ROS Production by AK3 in the Presence of Cisplatin
We studied the generation of ROS in the parental SV-HUC-1
and SCaBER cells after exposure to cisplatin in the presence or
absence of AK3 overexpression. Exposure of the cells to cisplatin
alone led to a significant increase in ROS production in the
parental SC-HUC-1 and SCaBER cells, which was further
enhanced when the cells were treated with cisplatin in the
presence of AK3 overexpression (Figure 3a, d). The basal ROS
levels in CSC vapor exposed cells HUC1-6M and SCaBER-6M
were higher than those in parental cells (Figure 3c, f). As previously
noted, HUC1-6M and SCaBER-6M cells had acquired resistance
to cisplatin; treatment with cisplatin alone did not increase in ROS
production significantly, but treatment of the HUC1-6M and
SCaBER-6M cells with cisplatin in the presence of AK3
expression, enhanced the ROS production (Figure 3 b, e). The
mean fluorescence density of the cells is depicted in figures 3g and
3h .
AK3 Induced Release of Lactate Dehyderogenase upon
Treatment of Cisplatin
SV-HUC-1, HUC1-6M, SCaBER, and SCaBER-6M cells were
transfected with AK3 expression plasmid or the control plasmid.
24 h after transfection, cells were treated with cisplatin and the
cytotoxic effect of the drug on the cells was studied by measuring
LDH release in the culture medium, as an indicator of cell
membrane damage. Treatment of the parental SV-HUC-1 and
SCaBER cells with cisplatin alone or cisplatin in presence of AK3
expression plasmid led to significant release of LDH in the media
AK3 and Cisplatin Resistance
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e20806AK3 and Cisplatin Resistance
PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e20806(Figure 4a, b). Exposure to CSC vapor, however, increased the
basal levels of LDH in the medium both in SV-HUC1-6M and in
SCaBER-6M, compared with parental cell lines. As the CSC
vapor exposed cells had acquired resistance to cisplatin, treatment
of the HUC1-6M and SCaBER-6M cells with cisplatin alone did
not produce any significant change in the release of LDH. When
the cells were treated with cisplatin under AK3 overexpression,
LDH release was significantly increased in both HUC1-6M and
SCaBER-6M cells, indicating increased cellular membrane injury.
Activation of Apoptosis in the Presence of AK3 and
Cisplatin
Next we studied the induction of apoptosis by cisplatin in SV-
HUC-1 and HUC1-6M in the presence or absence of AK3.
Apoptosis was determined by staining cells with annexin V-
fluorescein isothiocyanate and propidium iodide (PI). 48 hrs of
cisplatin treatment induced 19.31% late apoptosis ( both annexin V
and PI positive) in SV-HUC-1 cells, with 4.8% of cells undergoing
early apoptosis (annexin V positive and PI negative), compared to
0.36% late apoptotic cells and 1.2% of early apoptotic cells in the
absence ofcisplatin(Figure 5a,b).Thesamedose ofcisplatindidnot
affect the apoptosis in HUC1-6M cells (Figure 5c, d), consistent with
the resistance phenotype of these cells to cisplatin. Overexpression
of AK3 alone did not induce any apoptosis (Figure 5e), but
importantly, the presence of AK3 potentiated the toxicity of
cisplatin by increasing apoptosis (Figure 5f).
CSC vapor induces Survival Proteins
As the CSC vapor exposed cells showed activation of pro-
apoptotic factors and yet were evading cell death due to apoptosis,
we next examined the expression of Bcl-2 family proteins in
response to CSC vapor. Western Blot analysis revealed that both
Bcl-xL and Bcl-2 protein expression increased in HUC1-6M and
SCaBER-6M cells compared to the parental cells (Figure 6a) but
the levels of Bax and Bad remained unaffected. Further, we
studied the release of cytochrome c in CSC vapor exposed cells in
response to cisplatin. Our data showed that there was less
cytochrome c release in response to cisplatin both in SCaBER-6M
and HUC1-6M cells compared to the parental cells (Figure 6b).
CSC Vapor Induces Cisplatin Resistance In Xenograft
Model
We next tested whether CSC vapor cells are resistance to
cisplatin in vivo. Athymic nude mice were injected subcutaneously
(s.c.) with either parental SCaBER cells or their counterparts
SCaBER-6M cells. At day 7 when the tumors reached the size of
approximately 50 mm
3, mice were randomized into two groups of
eight animals each and treated with either PBS or cisplatin
intraperitoneally. Tumor volumes were measured weekly and the
mean tumor volume was calculated. We observed a significant
increased growth rate of SCaBER-6M xenografts than the
parental ones over the 60-day experimental period (P,0.01;
Figure 7a). In addition, treatment of mice bearing SCaBER
xenografts with cisplatin resulted in a marked inhibition of tumor
growth compared to their PBS controls (P,0.05, Figure 7a).
However, treatment with cisplatin was ineffective in inhibiting the
growth of tumors derived from SCaBER-6M cells (Figure 7a).
Discussion
Secondhand smoke exposure or exposure to environmental
smoke has been assessed as a risk of bladder cancer [22]. Our
approach here is based on recent studies on normal oral
keratinocytes indicating that exposure of cells to vapor component
Figure 2. DYm Alteration by AK3 in the Presence of Cisplatin. Mitochondrial membrane potential was measured in SV-HUC1, HUC1-6M (a),
SCaBER and SCaBER-6M (b) cells transfected with AK3 or control vector, followed by treatment with cisplatin for 48 h. Cells were stained with JC-1
reagent and cell fluorescence was measured on a flow cytometer using Fl1 and Fl2 channels. Increase of red fluorescence indicates hyper-polarization
of mitochondrial membrane potential (A ¨Ym). * indicates P,0.05 and ** indicates P,0.01.
doi:10.1371/journal.pone.0020806.g002
Figure 1. CSC vapor decreased the expression of AK3 and increased cisplatin resistance. (a) Western blot analysis was performed using
anti-AK3 and anti-AK2 antiserum. Protein extracts in each lane are as indicated. Even loading was confirmed by re-probing the membrane with b-
Actin antibody. HUC1-6M or SCaBER-6M indicates the cells chronically exposed to CSC vapor. HUC1-0.1%6M are SV-HUC-1 cells exposed to 0.1% CSC
for 6 months. SV-HUC-1 and HUC1-6M (b), SCaBER and SCaBER-6M (c) were treated with 0 to 5 mg/ml cisplatin for 48 h, or with 3 mg/ml cisplatin for
24, 48 and 72 h, in the presence and absence of AK3 as indicated. (d) Colony formation assays were performed with SCaBER and SCaBER-6M in the
presence and absence of AK3 as indicated. Data were expressed as mean 6SD. * indicates P,0.05 (e) SV-HUC-1 and SCaBER cells were transfected
with AK3 RNAi for 48 h and Western blot analysis was performed using anti-AK3 antiserum. (f) SCaBER cells were transfected with AK3 RNAi and 48 h
after transfection the cells were treated with 0 to 5 mg/ml cisplatin for 48 h and cellular survival was assessed. Error bars represent standard deviation
of three experiments.
doi:10.1371/journal.pone.0020806.g001
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cigarette smoke extract[21]. These studies also indicated that
chronic exposure to cigarette smoke provide a better model in vivo
than acute exposure to cigarette smoke [21]. Studies with
environmental cigarette smoke or secondhand smoke in mice
have demonstrated a variety of early alterations, including
cytogenetic damage in bone marrow and peripheral blood,
formation of lipid peroxidation products in lung, increase of bulky
DNA adducts and oxidatively generated DNA damage[23,24].
Our observation in this model that AK3 protein expression is
decreased by CSC vapor builds on an old observation that
cigarette smoke poisons lung cilia through a direct effect on
adenylate kinases [25]. Also increase of AK3 mRNA level and AK3
enzyme activity were previously observed in rat skeletal muscle
[26]. In addition, AK3 protein was found to increase 10-fold
during neural differentiation of P19 embryonal carcinoma cells
[27]. The induction of AK3 mRNA was also shown in response to
hypoxia in HeLa cells depending on the presence of hypoxia-
inducible factor-1 [28]. Here we show a direct effect on cancer
cells and provide novel evidence that decreased expression of AK3
in the presence of CSC vapor is accompanied with decreased
sensitivity of bladder cells to cisplatin and restoration of AK3
sensitizes cells to cisplatin. By linking AK3, our data support the
notion that mitochondria plays an important role in cigarette
smoke induced cisplatin resistance. Studies indicate that compo-
nents present in cigarette smoke extract are able to pass through
Figure 3. ROS Production by AK3 in the Presence of Cisplatin. ROS production was measured in parental SV-HUC-1 and SCaBER cells or cells
exposed to CSC vapor for 6 months using DCFH-DA staining. The cells were transfected with or without the AK3 expression plasmid and treated with
or without cisplatin for 48 h before staining. ROS generation in SV-HUC-1 and HUC1-6M (a–c) and SCaBER and SCaBER-6M (d–f) cells with
overexpression of AK3 with and without cisplatin. The mean fluorescence density was calculated and data was plotted as mean 6 SD (g,h).
doi:10.1371/journal.pone.0020806.g003
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proven that highly reactive components like polycyclic aromatic
hydrocarbons, aldehydes, phenols, heavy metals, and amines are
lipophilic candidates that easily enter the cell and disturb
mitochondria [31,32]. AK3 is present in the mitochondrial matrix
and probably functions in transferring the high-energy phosphate
to AMP from GTP that is synthesized by the TCA cycle [33,34].
Decrease of cellular ATP and rapid depolarization of mitochon-
drial membrane potential and induction of apoptosis by cigarette
smoke have been well established in various forms of cancer
[30,35].
Theroleofmitochondria incisplatinresistance is further supported
by recent data which showed that cisplatin may directly interact with
Figure 4. AK3 Induced Release of Lactate Dehyderogenase upon Treatment of Cisplatin. LDH release in SV-HUC-1 (a) and SCaBER (b) cells
exposed to CSC vapor in presence of AK3 followed by cisplatin treatment for 48 h. The data are presented as means 6 SD. All experiments were
performed in triplicate. Statistical significance is as indicated with * indicates P,0.05 and ** indicates P,0.01.
doi:10.1371/journal.pone.0020806.g004
Figure 5. Activation of Apoptosis in the Presence of AK3 and
Cisplatin. Apoptosis was measured in the SV-HUC-1 and HUC1-6M
cells using annexin/PI staining. The cells were transfected with or
without AK3 expression plasmid and treated with or without cisplatin
for 48 h as indicated.
doi:10.1371/journal.pone.0020806.g005
Figure 6. CSC vapor induces Survival Proteins. (a) Cellular lysates
were obtained from the indicated cell lines and subjected to Western
Blot analysis using the indicated antibodies. b-actin was used as a
control. (b) The indicated cell lines were treated with 3 mg/ml cisplatin
for 48 h. Mitochondrial and cytoplasmic total cellular lysates were
subjected to Western Blot analysis using anti-cytochrome c antibody.
Protein extracts in each lane are as indicated. Immunodetection of a ˆ-
actin and COX II were done to assure that the transfected proteins were
in cytoplasm and mitochondria respectively.
doi:10.1371/journal.pone.0020806.g006
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inter- and intra-strand nuclear DNA crosslinks. However, only a low
percentage of intracellular platinum is bound to nuclear DNA, while
a great majority of the intracellular drug interacts with nucleophilic
sites on other molecules, including mitochondrial DNA [37,38].
Mitochondrial DNA-cisplatin adducts may be more common than
cisplatin adducts with nuclear DNA in the same cell line treated with
the same concentration of cisplatin [39,40]. Furthermore, Yang et al
[41] showed thatglutathione counteracted thecytotoxicity ofcisplatin
by preventing ROS production rather than inhibiting formation of
platinum/DNA adducts.
Mitochondria are the predominant source of ROS produced in
most apoptotic systems and mitochondrial homeostasis is critical in
regulating apoptosis [42]. In a normal system, apoptosis at the
mitochondrial level is initiated by depolarization of the mitochon-
drial membrane, followed by release of cytochrome c. Other
mitochondrion-related cellular alterations that are important in
modulating apoptotic include (but not limited to) induction of
ROS. We observed that CSC vapor-selected acquisition of
resistance to cisplatin was marked by the presence of decreased
mitochondrial membrane potential (DYm, i.e increased depolar-
ization) and increased basal levels of ROS. Comparable levels of
ROS generation and DYm depolarization might have resulted in
cellular apoptosis and cell death in unexposed cells. However, we
also observed that chronic CSC exposed cells are resistant to DYm
depolarization-induced apoptosis (data not shown). Similar
findings were also reported in an oral keratinocytes [21]. AK3 is
a mitochondrial-matrix protein which is downregulated by chronic
CSC exposure. We observed decreased DYm (i.e increased
depolarization) and increase in ROS production in AK3
overexpressed, cisplatin treated cells. Studies have indicated
activation of NF-kB, histone modification and chromatin
remodeling in response to CSC [43]. Studies by the same group
also indicate an increase in NF-kB in response to ROS [44].
Mitochondrial death signaling via multi domain Bcl-2 family
members Bax and Bak can be interrupted by Bcl-xL, an anti-
apoptotic member of the Bcl-2 family, which sequesters and
counteracts the proaopototic signals [45]. Our results indicate an
increase in the expression of Bcl-xL in the CSC vapor exposed
cells compared to the parental cells. Bcl-xL has been found to be
up-regulated in breast cancer cells lines and primary breast tumors
and is considered a marker for increased tumor grade and nodal
metastaisis [46]. Cells expressing Bcl-xL are more likely to survive
following DNA damage and can potentially accumulate new
somatic mutations at higher frequencies [47]. An increase in the
Bcl-xL/ Bax ratio provides DNA damage induced resistance and
survival to many cancer cell types [48]. Even though we observe
an increase in the basal levels of mitochondrial depolarization and
ROS generation in response to CSC vapor, these signals may be
counteracted by increase in the Bcl-xL/ Bax ratio, which may
increase the cellular survival of the cells due to selective pressure of
the surrounding environment which enable them to escape
apoptosis and acquire resistance to chemotherapeutic drugs.
Our current study does not rule out other mechanisms of
resistance to cisplatin, such as decreased uptake, inactivation by
nucleophilic compounds, or accelerated DNA repair, in CSC-
exposed urothelial cells [49] . In addition, the precise mechanism of
howAK3sensitizescellstocisplatinhas not yetbeenclearlydefined.
Of relevance to the studies herein, the linkage of translational
suppression of AK3 that mediate CSC vapor-induced toxicity and
cisplatin resistance that has not been previously reported. However,
new data links Pre-miR-181a and pre-miR-630 with modulation of
both mitochondrial and post mitochondrial steps of the intrinsic
pathway of apoptosis, including mitochondrial transmembrane
potential dissipation, in cisplatin resistant lung cancer cells [50] .
Studies are ongoing in our laboratory to understand these and other
cellular pathways involved in the regulation of AK3 in response to
CSC vapor and cisplatin.
Figure 7. CSC Vapor Induces Cisplatin Resistance In Xenograft Model. (a) Subcutaneous xenografts were generated in of 5- to 6-week-old
female athymic nu/nu mice with SCaBER or SCaBER-6M cells. One week following tumor cell inoculation, mice were treated with either PBS or
cisplatin (3 mg/Kg/dose). The mean tumor volume was calculated. * indicates P,0.01 (b) One representative mouse from each group was displayed.
doi:10.1371/journal.pone.0020806.g007
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Cell Culture
Normal uroepithelial cell line SV-HUC-1 (ATCC, Manassas,
VA) and bladder cancer cell line SCaBER (ATCC, Manassas,
VA) were maintained in F-12K medium and Dulbecco’s modified
Eagle’s medium respectively (Invitrogen, Carlsbad, CA) supple-
mented with 10% fetal bovine serum (Clontech, Mountain View,
CA). To study the vapor effect of the cigarette smoke condensate
(CSC, Murty Pharmaceuticals, Inc., KY), cells were also grown in
the smoking dedicated incubator without direct CSC treatment
[21]. Cells that were grown in a normal incubator that did not
have any cell lines treated with CSC are labeled as control or
parental. Cells that were grown and passaged in the incubator in
which cell lines were being exposed to CSC vapor are labeled as
6M treated cells or termed as passive smoked cells. The CSC
(100%) was stored at 280uC. For every two CSC treated flask, one
passive smoked flask was maintained. Hence forth the SV-HUC-1
and the SCaBER cells exposed to passive smoke were referred to
as HUC1-6M and the SCaBER-6M respectively. AK3 expression
plasmid was generated by cloning the ORF of the gene in the
pcDNA3.1+/Hygro plasmid using EcoRI and NotI sites. All clones
were sequenced to rule out any mutation.
Cell Viability Assay
SV-HUC-1, SCaBER, HUC1-6M and SCaBER-6Mcells were
grown in 35 mm, 6-well culture plates. The cells were transfected
with AK3 expression plasmid or the empty control vector using
Fugene HD (Roche, Indianapolis, IN) as per manufacturer’s
protocol. 24 h after transfection the cells were rinsed with Hanks’
Balanced Salt Solution (HBSS) and treated with 0, 1,2,3,4 or
5 mg/ml cisplatin or vehicle control for 48 h in complete medium
at 37uCi n5 %C O 2 incubator. After the desired time of exposure,
the drug containing medium was aspirated, the cells were rinsed
with HBSS and MTT assay was performed as described in [51].
Cell viability was also performed with Calcein AM (acetox-
ymethylester of Calcein, Invitrogen) assay with an excitation
frequency of 480 nm and an emission frequency of 535 nm [52].
.All experiments were done in triplicate. All cells were released of
passive smoking 24 h before each experiment unless otherwise
mentioned.
Colony formation assay
SCaBER and SCaBER-6M cells were transfected with either
empty vector or AK3 expression vector in 6-well plates. 24 hrs
later, cells were exposed to 100 mg/ml hygromycin to select
positively transfected cells. Cells were cultured with hygromycin
for 5 days. Cell colonies were then treated with 2 mg/ml cisplatin
for 2 days and grew for additional 5 days. Colonies were fixed with
10% formalin and stained with 0.4% crystal blue.
SiRNA Transfection
ON-TARGETplus SMARTpool control siRNA, AK3 siRNA
were purchased from Dharmacon (Lafayette, CO) and cells were
transfected with RNAiMAX reagent (Invitrogen, CA) according to
the manufacturer’s instructions. Briefly, cells were plated at a
density of 20,000/well in 12-well plates. The following day, a stock
solution containing 0.5 ml (20 mM) of siRNA (control, AK3) and
1 ml of transfection reagent per 250 ml of OptiMEM media
(Gibco, Carlsbad, CA) was prepared and incubated at room
temperature for 20 min. Media was aspirated from each well and
replaced with 500 ml of antibiotic-free culture medium (DMEM/
10% FBS) plus 250 ml of transfection mixture. Following an
overnight incubation, the transfection mixture was replaced with
complete culture media.
Western Blot
Whole cell extracts of SV-HUC-1, HUC1-6M and HUC1-
0.1%6M, SCaBER and SCaBER-6M and cells, were prepared
using RIPA buffer (10 mM Tris pH 7.4, 150 mM NaCl, 5 mM
EDTA, 1% Triton-X-100, 0.1% SDS) containing protease
inhibitors (Roche, Indianapolis, IN cat # 1697498) and 1 mM
PMSF. Western blot analysis was performed as described in [53]
using 30 mg protein lysates for each protein antibody studied.
Mitochondrial and cytoplasmic fractions were prepared as
described in [54]. Nitrocellulose membranes were hybridized with
primary antibodies and developed with Amersham developer as
per the manufacturer’s instructions.
Measurement of Mitochondrial Membrane Potential
Activity
We used a fluorescent dye JC-1 to measure changes in
mitochondrial membrane potential [55]. Once loaded into the
mitochondria, JC-1 undergoes aggregate formation in the regions
of high potential. This method has been validated for a reliable
analysis of DYm changes in mitochondria [56]. The green
fluorescent JC-1 (5,59, 6,69-tetrachloro-1,19,3,39-tetraethylbenzi-
midazolylcabocyanine iodine, T-3168) exists as a monomer at low
membrane potential. Mitochondrial function was monitored
following treatment of SV-HUC-1, SCaBER, HUC1-6M and
SCaBER-6M cells with cispaltin for 48 h. Briefly, after experiment
treatment cells were incubated for 15 minutes at 37uC in the 5%
CO2 incubator in the presence of 10 mM of the JC-1 and cells
were analyzed using FACStar flow cytometer (Becton Dickinson,
Franklin Lakes, NJ) as per manufacturer’s instructions (Stratagene,
La Jolla, CA).
Determination of Reactive Oxygen Species
DCFH-DA ( Invitrogen, CA) was used for Reactive Oxygen
Species (ROS) detection. DCFH-DA is cleaved intracellularly by
nonspecific esterases to form DCFH, which is further oxidized by
ROS to form the fluorescent compound DCF[57]. SV-HUC-1,
SCaBER, HUC1-6M and SCaBER-6M cells were treated with or
without cisplatin for 48 h, DCFH-DA working solution was added
directly to the medium to reach 2 mM, and then incubated at 37uC
for 30 min. Cells were then washed once, re-suspended in PBS
and kept on ice for an immediate detection by FACScan (Becton
Dickinson, USA). Mean fluorescence was generated using the
software ‘‘Cell Quest’’ (Becton Dickinson, USA).
Cytotoxicity assays
Membrane damage was evaluated by measuring the release of
lactate dehydrogenase (LDH) in the culture medium [58]. SV-
HUC-1, SCaBER, HUC1-6M and SCaBER-6M cells were
treated with or without cisplatin for 48 h, before the media was
collected for the LDH release assay. A control blank was run at all
times without any cells. LDH is an oxidoreductase which catalyzes
the inter-conversion of lactate and pyruvate. The assay is based on
the reduction of NAD by the action of LDH. The resulting
reduced NAD (NADH) is utilized in the stoichiometric conversion
of a tetrazolium dye. The resulting colored compound was
measured spectrophotometrically (A490 nm–A690 nm) using a Mo-
lecular Devices Spectra Max 250, 96 well plate reader (Sunnyvale,
CA). The LDH-cytotoxicity detection kit (Roche Diagnostics,
Indianapolis, IN) was used for all experiments. Each experiment
was done in triplicate.
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Apoptosis was determined by staining cells with annexin V-
fluorescein isothiocyanate (FITC) and PI labeling as per
manufacturer’s instructions (Becton Dickinson, Franklin Lakes,
NJ). Annexin V was used to detect early apoptotic cells during
apoptotic progression. Briefly, SV-HUC-1, SCaBER, HUC1-6M
and SCaBER-6M cells were treated with or without cisplatin for
48 h. The prepared cells were washed twice with cold PBS, re-
suspended in 100 m l of binding buffer at a concentration of 1610
6
cells/ml and stained with Annexin V and PI. The cells were
analyzed on the FACStar flow cytometer (Becton Dickinson,
Franklin Lakes, NJ). Data analysis was done using the software
‘‘Cell Quest’’.
Tumor Xenograft Study
Subcutaneous xenografts were generated in 5- to 6-week-old
female athymic nu/nu mice (NIH) with SCaBER or SCaBER-6M
(5610
6 cells/mouse) cells. One week following tumor cell
inoculation, sixteen mice with successfully engrafted SCaBER or
SCaBER-6M xenografts were randomized into two cohorts of
eight animals each group and treated with either PBS or cisplatin
(3 mg/Kg/dose, intraperitoneally). Tumor volumes were mea-
sured using digital calipers (Fisher Scientific) once per week and
the mean tumor volume was calculated. Mouse experiments
described here were done according to the guidelines of the
Animal Care and Use Committee of Johns Hopkins Medical
Institutions. Mice were maintained in accordance to the guidelines
of the American Association of Laboratory Animal Care.
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